Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
- Chemical substance: Sirolimus
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Sirolimus 1mg tablets
0802020U0AAADAD
|
Sirolimus | Sirolimus | Malignant Disease and Immunosuppression | 745 |
|
Sirolimus 2mg tablets
0802020U0AAAEAE
|
Sirolimus | Sirolimus | Malignant Disease and Immunosuppression | 443 |
|
Sirolimus 500microgram tablets
0802020U0AAAFAF
|
Sirolimus | Sirolimus | Malignant Disease and Immunosuppression | 187 |
|
Rapamune 1mg tablets
0802020U0BBADAD
|
Rapamune | Sirolimus | Malignant Disease and Immunosuppression | 77 |
|
Sirolimus 1mg/ml oral solution sugar free
0802020U0AAACAC
|
Sirolimus | Sirolimus | Malignant Disease and Immunosuppression | 51 |
|
Rapamune 2mg tablets
0802020U0BBAEAE
|
Rapamune | Sirolimus | Malignant Disease and Immunosuppression | 36 |
|
Rapamune 0.5mg tablets
0802020U0BBAFAF
|
Rapamune | Sirolimus | Malignant Disease and Immunosuppression | 15 |
|
Rapamune 1mg/ml oral solution
0802020U0BBACAC
|
Rapamune | Sirolimus | Malignant Disease and Immunosuppression | 4 |
|
Hyftor 2mg/g gel
0802020U0BCAAAG
|
Hyftor | Sirolimus | Malignant Disease and Immunosuppression | No data available |
|
Sirolimus 2mg/g gel
0802020U0AAAGAG
|
Sirolimus | Sirolimus | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.